Potassium Citrate NDC 0591-2742

NDC codes

FDA NDC Directory

Product NDC (as listed)0591-2742Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00591-2742Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0591-2742-01	00591274201	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0591-2742-01)Marketed from May 30, 2018

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Potassium Citrate
Generic name (nonproprietary): potassium citrate
Active ingredients: Potassium citrate — 15 meq/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Actavis Pharma, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209758
Marketing start: May 30, 2018
Marketing end: Feb 28, 2027
Other FDA classes: Acidifying Activity (Mechanism)Calcium Chelating Activity (Mechanism)Decreased Coagulation Factor Activity (Physiologic effect)
Identifiers: Product ID 0591-2742_309b143e-7142-4a21-859e-715ba61e82f7SPL ID 309b143e-7142-4a21-859e-715ba61e82f7SPL set ID ac173781-486b-461c-97ae-8b5c69e20792RxCUI 199376, 199381, 898490UNII EE90ONI6FF
Pharmacologic class: Anti-coagulant; Calculi Dissolution Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400591274201 followed by a unit qualifier and the quantity

Package 00591-2742-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 1, 2022.

Indications (excerpt from the label)

Potassium Citrate extended-release tablets are a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )]. 1.3 Uric Acid Lithiasis with or without Cal…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209758

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209758
Product	Strength	Form · route	Labeler	Product NDC
Potassium Citrate	Potassium citrate 10 meq/1	Tablet, Extended releaseOral	Actavis Pharma, Inc.	0591-2729
Potassium Citrate	Potassium citrate 10 meq/1	Tablet, Extended releaseOral	Bryant Ranch Prepack	63629-8759
Potassium Citrate	Potassium citrate 5 meq/1	Tablet, Extended releaseOral	Actavis Pharma, Inc.	0591-2682